None yet. When a new project in the record names DLA Piper as owner, partner or investor, it shows here.
Adds macrocyclic peptide platform to broaden immunology toolbox, enabling oral and long‑acting drug development; deal up to $1.15 billion.
Sale covers botanical extracts, vitamins & minerals, natural colors, antioxidants and certain Peru flavor activities; operations generated ~$170M in 2025 and employ ~600 across five plants; expected close by end‑2026.